View Item 

Show simple item record

Effect of Race and Ethnicity on Antihypertensive Medication Utilization Among Women in the United States: Study of Women’s Health Across the Nation (SWAN)
dc.contributor.authorJackson, Elizabeth A.
dc.contributor.authorRuppert, Kristine
dc.contributor.authorDerby, Carol A.
dc.contributor.authorLian, Yinjuan
dc.contributor.authorNeal‐perry, Genevieve
dc.contributor.authorHabel, Laurel A.
dc.contributor.authorTepper, Ping G.
dc.contributor.authorHarlow, Siobán D.
dc.contributor.authorSolomon, Daniel H.
dc.date.accessioned2017-11-13T16:40:39Z
dc.date.available2018-05-04T20:56:59Zen
dc.date.issued2017-03
dc.identifier.citationJackson, Elizabeth A.; Ruppert, Kristine; Derby, Carol A.; Lian, Yinjuan; Neal‐perry, Genevieve ; Habel, Laurel A.; Tepper, Ping G.; Harlow, Siobán D. ; Solomon, Daniel H. (2017). "Effect of Race and Ethnicity on Antihypertensive Medication Utilization Among Women in the United States: Study of Women’s Health Across the Nation (SWAN)." Journal of the American Heart Association (3): n/a-n/a.
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/2027.42/139083
dc.publisherAcademic Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherdisparities
dc.subject.othermedication
dc.subject.otherrace/ethnicity
dc.subject.otherwomen
dc.subject.otherhypertension
dc.titleEffect of Race and Ethnicity on Antihypertensive Medication Utilization Among Women in the United States: Study of Women’s Health Across the Nation (SWAN)
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139083/1/jah32010.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139083/2/jah32010_am.pdf
dc.identifier.doi10.1161/JAHA.116.004758
dc.identifier.sourceJournal of the American Heart Association
dc.identifier.citedreferencePsaty BM, Lumley T, Furberg CD. Metaâ analysis of health outcomes of chlorthalidoneâ based vs nonchlorthalidoneâ based lowâ dose diuretic therapies. JAMA. 2004; 292: 43 â 44.
dc.identifier.citedreferenceMozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics C and Stroke Statistics S. Heart disease and stroke statisticsâ 2016 update: a report from the American Heart Association. Circulation. 2016; 133: e38 â e360.
dc.identifier.citedreferenceRoger VL, Go AS, Lloydâ Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statisticsâ 2012 update: a report from the American Heart Association. Circulation. 2012; 125: e2 â e220.
dc.identifier.citedreferenceFranco OH, Peeters A, Bonneux L, de Laet C. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005; 46: 280 â 286.
dc.identifier.citedreferenceFerdinand KC, Ferdinand DP. Raceâ based therapy for hypertension: possible benefits and potential pitfalls. Expert Rev Cardiovasc Ther. 2008; 6: 1357 â 1366.
dc.identifier.citedreferenceHertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med. 2005; 165: 2098 â 2104.
dc.identifier.citedreferencePrevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265: 3255 â 3264.
dc.identifier.citedreferenceStaessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised doubleâ blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Systâ Eur) Trial Investigators. Lancet. 1997; 350: 757 â 764.
dc.identifier.citedreferenceMajor outcomes in highâ risk hypertensive patients randomized to angiotensinâ converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipidâ Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981 â 2997.
dc.identifier.citedreferenceMajor cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidâ lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000; 283: 1967 â 1975.
dc.identifier.citedreferenceChobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42: 1206 â 1252.
dc.identifier.citedreferenceJames PA, Oparil S, Carter BL, Cushman WC, Dennisonâ Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidenceâ based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311: 507 â 520.
dc.identifier.citedreferenceSowers M, Crawford SL, Sternfeld B, Morganstein D, Gold E, Greendale G, Evans D, Neer R, Matthews K, Sherman S, Lo A, Weiss G, Kelsey J. SWAN: a multiâ center, multiâ ethnic, communityâ based cohort study of women and the menopausal transition. In: Kelsey J, Lobo RA, Marcus R, eds. Menopause: Biology and Pathobiology. San Diego: Academic Press; 2000: 175 â 188.
dc.identifier.citedreferenceJohnston JM, Colvin A, Johnson BD, Santoro N, Harlow SD, Bairey Merz CN, Suttonâ Tyrrell K. Comparison of SWAN and WISE menopausal status classification algorithms. J Womens Health (Larchmt). 2006; 15: 1184 â 1194.
dc.identifier.citedreferencePatetta M. SAS, Longitudinal Data Analysis With Discrete and Continuous Responses. Cary, NC: SAS Institute; 2007.
dc.identifier.citedreferenceOng KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999â 2004. Hypertension. 2007; 49: 69 â 75.
dc.identifier.citedreferenceGu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation. 2012; 126: 2105 â 2114.
dc.identifier.citedreferenceGu Q, Pauloseâ Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation. 2006; 113: 213 â 221.
dc.identifier.citedreferenceWright JT Jr, Probstfield JL, Cushman WC, Pressel SL, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis KL, Oparil S, Black HR, Alderman MH; ALLHAT Collaborative Research Group. ALLHAT findings revisited in the context of subsequent analyses, other trials, and metaâ analyses. Arch Intern Med. 2009; 169: 832 â 842.
dc.identifier.citedreferenceStafford RS, Monti V, Furberg CD, Ma J. Longâ term and shortâ term changes in antihypertensive prescribing by officeâ based physicians in the United States. Hypertension. 2006; 48: 213 â 218.
dc.identifier.citedreferenceDahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballeâ Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995 â 1003.
dc.identifier.citedreferenceDahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Angloâ Scandinavian Cardiac Outcomes Trialâ Blood Pressure Lowering Arm (ASCOTâ BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895 â 906.
dc.identifier.citedreferenceLindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A metaâ analysis Lancet. 2005; 366: 1545 â 1553.
dc.identifier.citedreferenceKramer H, Han C, Post W, Goff D, Diezâ Roux A, Cooper R, Jinagouda S, Shea S. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multiâ Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2004; 17: 963 â 970.
dc.identifier.citedreferenceWright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB; ALLHAT Cooperative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293: 1595 â 1608.
dc.identifier.citedreferenceEinhorn PT, Davis BR, Wright JT Jr, Rahman M, Whelton PK, Pressel SL; ALLHAT Cooperative Research Group. ALLHAT: still providing correct answers after 7 years. Curr Opin Cardiol. 2010; 25: 355 â 365.
dc.identifier.citedreferenceCushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, Oparil S, Probstfield JL, Whelton PK, Wright JT Jr, Alderman MH, Basile JN, Black HR, Grimm RH Jr, Hamilton BP, Haywood LJ, Ong ST, Piller LB, Simpson LM, Stanford C, Weiss RJ; ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipidâ Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012; 14: 20 â 31.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jah32010.pdf
Size:
440.0KB
Format:
PDF
View/Open
Name:
jah32010_am.pdf
Size:
277.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.